I don't know if Cochrane ever said explicitly who the target audience was. I don't think it is researchers though. The reviews were seen as providing systematic analysis of the benefits and disadvantages of treatment modalities in a form that would be useful in the building of a consensus for medical training and continuing education of the medical community.
When Cochrane reviews started coming out they were welcomed as unbiased and systematic summaries for management in areas where one had not oneself carefully scrutinised the evidence. This might seem peculiar but medics have always worked on the basis that they have certain areas of special interest where they make it their responsibility to be completely up to date and to form their own judgment on treatments but also want to be broadly familiar with the treatment options in areas that their work might overlap with. So, for instance, if I had a rheumatology patient with bone pain and found a high calcium level, I would be thinking of the possibility of myeloma, and would want to be aware of the current state of options for treatment in myeloma in general terms because I might want to refer to a haematologist for diagnosis and treatment.
In this way Cochrane reviews were seen as serving a function a bit like the BMJ, or Journal of the American Medical Association, which kept doctors abreast of management options on a broad front, not so much to provide specific new findings as to update the wider knowledge base needed to judge how to handle problems outside one's immediate focus.
For general practitioners Cochrane reviews might have been particularly important because GPs rarely had the opportunity to scrutinise recent evidence on a topic in detail in the way specialist physicians would do at society meeting and in journal clubs.
Interesting. So like many professions such as human resources have the CIPD to keep them up to date, seeking professional current legal advice on a legal matter etc. The whole thing begins with the correct diagnosis and that depends on education and training and application, a root and branch problem.
I'm beginning to wonder if Cochrane is really now saying that in 2024 the theory behind this illness and the state of knowledge from research has not moved past the Chief Medical Officer's Report 2002 with the addition of the WHO Patient Safety arm from 2004. Safety and efficacy as Helskinki emphasise not efficacy and safety as most research emphasises.